Dr. Blevins on GLP Medications: Understanding Their Role in Diabetes and Weight Loss

Understanding GLP-1 and GIP Hormones

• 💡 GLP-1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptide) are naturally occurring hormones produced in the small intestine after eating.
• 🧠 GLP-1 stimulates insulin production, suppresses glucagon release from the liver, slows gastric emptying, and reduces appetite.
• 🎯 GIP primarily stimulates insulin production and may also contribute to appetite reduction and improved insulin sensitivity.
• ⚠️ While these hormones are present in individuals with both Type 1 and Type 2 diabetes, their effects are often reduced in Type 2 diabetes, making GLP-1 mimicking medications beneficial.

GLP-1 Medications and Their Mechanisms

• 🚀 Medications like Ozempic, Wegovy, Mounjaro, and Zepbound mimic these natural hormones to aid in managing diabetes and weight loss.
• 🍽️ A key mechanism is slowing gastric emptying, which leads to feeling full faster and reducing overall calorie intake.
• 🧠 These medications also appear to have a central effect on the brain, directly suppressing appetite.
• ⚖️ The half-life of these medications varies, influencing dosing frequency; for example, semaglutide (Ozempic/Wegovy) has a week-long half-life, allowing for once-weekly injections, while tirzepatide (Mounjaro/Zepbound) has a 5-day half-life.

GLP-1s in Type 1 Diabetes: Potential and Caution

• ⚠️ GLP-1 medications are currently approved for Type 2 diabetes, not Type 1, due to concerns about increased risk of hypoglycemia and diabetic ketoacidosis (DKA) in early studies.
• 📈 However, some studies showed benefits like reduced A1C and weight loss, with potential for improved insulin sensitivity and reduced insulin dosage.
• 🔬 Ongoing research, such as the CARMO study, is investigating the safety and efficacy of these medications specifically in individuals with Type 1 diabetes who are overweight or obese.
• 🧑‍⚕️ Off-label use in Type 1 diabetes is possible but requires careful consideration of risks, potential benefits, and close medical supervision, especially regarding insulin dose adjustments.

Weight, Obesity, and Medical Implications

• 📊 Overweight (BMI ≥ 27) and obesity (BMI ≥ 30) are associated with increased risks of high blood pressure, high cholesterol, Type 2 diabetes, and insulin resistance.
• 🌳 Environmental factors, genetics, and lifestyle choices all contribute to the rising rates of overweight and obesity across all age groups.
• 💊 GLP-1 medications are approved for weight loss in individuals meeting specific BMI criteria, especially when associated with comorbidities like cardiovascular disease.
• 🔄 Long-term treatment is often necessary, as the effects on appetite can diminish if the medication is stopped, leading to potential weight regain.

Side Effects and Considerations

• 🤢 Gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation, are common but often manageable and may improve over time.
• ⚠️ Slowed gastric emptying can be a concern, particularly for individuals with pre-existing gastroparesis, and requires careful monitoring.
• 📉 Not everyone experiences significant weight loss or tolerates the medications well; individual responses vary greatly.
• 💡 Cutting back on high-fat foods can help mitigate some GI side effects, and consistent hydration and bowel regularity are important.

Future Outlook and Research

• 📈 The high demand for GLP-1 medications suggests their significant perceived benefits, though supply chain issues have been a challenge.
• 🔬 Continued research is crucial to expand understanding of their use in various populations, including those with Type 1 diabetes, PCOS, and other metabolic conditions.
• 🍎 There is a long-term hope that these medications could contribute to generational shifts in eating habits and overall health awareness.
• 🤝 Collaboration between pharmaceutical companies, researchers, and patient advocacy groups is vital for advancing the study and accessibility of these transformative treatments.